Biotech Active runners: Gilead Sciences (NASDAQ:GILD), Inovio Pharmaceuticals (NYSEMKT:INO), Ariad Pharmaceuticals (NASDAQ:ARIA), Mann Kind Corporation (NASDAQ:MNKD)

Gilead Sciences (NASDAQ:GILD) EVP Norbert W. Bischofberger sold 90,000 shares of the stock on the open market in a transaction that occurred on Monday, April 14th. The shares were sold at an average price of $67.03, for a total transaction of $6,032,700.00. Gilead Sciences, Inc. (NASDAQ:GILD) shares after opening at $69.32 moved to $69.89 on last trade day and at the end of the day closed at $69.28. Company price to sales ratio in past twelve months was calculated as 9.51 and price to cash ratio as 49.98. Gilead Sciences, Inc. (NASDAQ:GILD) showed a negative weekly performance of -1.94%.

Inovio Pharmaceuticals Inc (NYSEMKT:INO) on Apr. 1 announced the appointment of E.J. Brandreth as Vice President of Quality. He will be responsible for all quality and compliance functions for a company that is moving forward with numerous late and early stage clinical trials and scaling up manufacturing and other operational areas to support its broad pipeline of immunotherapies and DNA vaccines. He will report to Inovio’s Chief Operating Officer Dr. Niranjan Sardesai. Prior to joining Inovio, Mr. Brandreth had a successful career transitioning start-up clinical biotech operations into successful commercial entities; he supported the growth of several pharmaceutical companies in the quality and compliance areas. Inovio Pharmaceuticals Inc (NYSEMKT:INO) shares advanced 2.69% in last trading session and ended the day on $2.67. INO return on equity ratio is recorded as -144.40% and its return on assets is -92.70%. Inovio Pharmaceuticals Inc (NYSEMKT:INO) yearly performance is 368.42%.

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) announced the appointment of Hugh M. Cole to the position of senior vice president and chief business officer. Mr. Cole will be responsible for global business and corporate development, licensing and strategic planning. He will report to ARIAD’s chairman and chief executive officer, Harvey J. Berger, M.D. Mr. Cole is a seasoned pharmaceutical executive with more than 25 years of industry experience and a deep background in rare and orphan pharmaceutical markets. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) shares moved down 6.05% in last trading session and was closed at $7.09, while trading in range of $ 6.66 – 7.10. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) year to date (YTD) performance is 4.11%.

Mann Kind Corporation (NASDAQ:MNKD)’s shares gained 0.16% to $6.29. The company on Apr. 7 announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) date for AFREZZA(R) by three months to July 15, 2014 in order to provide time for a full review of information submitted by Mann Kind in response to the FDA’s requests. Mann Kind Corporation (NASDAQ:MNKD) weekly performance is -8.71%. On last trading day company shares ended up $6.39. MannKind Corporation (NASDAQ:MNKD) distance from 50-day simple moving average (SMA50) is 9.14%. Analysts mean target price for the company is $7.57.